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ABSTRACT
Seasonal influenza can have serious morbid consequences and can even result in death, particularly in at-
risk populations, including healthcare professionals (HCPs), elderly and those living with a medical risk
condition. Although in Europe recommendations exist for annual influenza vaccination in these
populations in most countries, the vaccination coverage rate (VCR) is often well below the World Health
Organization target of 75% coverage. In our previous survey in 2009 we showed that some elements of
national vaccination policies, e.g. reminder systems, strong official recommendation, and easy access,
seemed to contribute to achieving higher influenza VCRs among elderly. We repeated the survey in 2016,
using the same methodology to assess changes in influenza VCRs among the elderly and in the impact of
policy elements on these VCRs. In addition, we collected information about VCRs among HCPs, and those
living with a medical risk condition. The median VCR in the 21 countries that had recommendations for
influenza vaccination in the elderly was 35.3%, ranging from 1.1% in Estonia to 74.5% in Scotland. The
average VCRs for HCPs and those living with medical risk conditions, available in 17 and 10 countries,
respectively, were 28.3% (range 7% in Czech Republic to 59.1% in Portugal) and 32.2% (range from 20.0%
in the Czech Republic and Hungary to 59.6% in Portugal), respectively. Fewer countries were able to
provide data from HCP and those living with medical risk conditions. Since the initial survey during the
2007–2008 influenza season, VCRs have decreased in the elderly in the majority of countries, thus,
achieving high VCRs in the elderly and the other target groups is still a major public health challenge in










Influenza, a highly contagious respiratory infectious disease
that can result in severe illness and death, is caused by influenza
viruses which circulate throughout the world. The World
Health Organization (WHO) have estimated that the annual
influenza epidemics result in about 3 to 5 million cases of
severe illness and about 250 000 to 500 000 deaths, thus influ-
enza is a significant global public health burden.1 Influenza can
trigger secondary infections and exacerbate pre-existing
chronic medical conditions, leading to severe complications
and increased morbidity and mortality. The annual number of
deaths due to influenza in Europe, estimated at 38,500 in 2013,
is higher than that due to car accidents, estimated at 25,900.2
In addition to this significant clinical impact, influenza has
major economic consequences through a range of direct and
indirect costs, e.g., medical treatment of influenza illness, loss
of productivity and absenteeism.3
Safe and effective influenza vaccines are available and have
been used for more than 60 years.4 These vaccines can provide
protection even when the vaccine viruses do not exactly match
the circulating viruses. WHO has stated that the most effective
way to prevent influenza is vaccination.1 WHO has identified
groups of people at higher risk of serious influenza complications
and the people who live with, or care for high risk individuals as
specific vaccination target groups. They recommend annual
influenza vaccination for pregnant women (at any stage of preg-
nancy), children aged between 6 months to 5 years, elderly
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individuals (aged >65 years), individuals with chronic medical
conditions and healthcare professionals (HCPs). In 2009 the
Council of the European Union set a target of 75% coverage
among all defined target groups by 2014/15.5 In Europe, in the
2012–2013 influenza season it was estimated that only about
80 million of the 180 million Europeans for whom seasonal influ-
enza vaccination is recommended are vaccinated, giving <45%
coverage.3 To achieve the 75% target rate, an additional 57.4 mil-
lion people need to be vaccinated. If this target coverage were to
be achieved, results from a statistical model suggest that the
impact on the average annual influenza-related events averted
would include 1.6 to 1.7 million fewer influenza cases, 678,500 to
767,800 fewer physician visits, 883,800 to 1,015,100 fewer lost
days of work, 23,800 to 31,400 fewer hospitalizations and 9,800
to 14,000 deaths avoided resulting in 190€ to 226€ million sav-
ings of influenza-related costs.4
HCPs are at risk of being exposed to patients infected with
influenza and if they become infected themselves they can play
a role in nosocomial transmission.1,6 This makes them an
important target group for influenza vaccination, not only for
direct protection against influenza infection and prevent sick
leave during epidemics but also to prevent transmission to
patients and their families. Many studies have reported high
rates of influenza vaccine hesitancy among HCPs, often due to
misconceptions about their own risk and influenza vaccine
effectiveness.6-8
We report the results from a follow-up study performed to
assess changes in VCRs and changes in policy elements since
2008. We also expanded the survey to additional EU Member
and Adriatic States and sought to identify national policy ele-
ments that may contribute to higher seasonal influenza VCRs
for the elderly. This study was based on a similar survey process
that we used previously to assess the impact of policy elements
on VCR in the elderly (Blank et al, 2012). In the current study
we expanded the populations of interest to include HCPs and
those living with a medical risk condition (i.e. treatment-
induced and/or disease-induced immunosuppression, meta-




The VCRs for the elderly were below the recommended 75%
threshold set by the Council of the European Union for the
2013–14, 2014–15 and 2015–16 seasons. In The Netherlands,
England and Scotland these were 64% or higher in the 2015–16
season, but the rates decreased over the three seasons
(Figure 1A). In contrast with the other countries where the
VCRs were either stationary or declined over the three seasons,
the VCR in Portugal increased to 67.9% in the 2015–16 season
from 57% and 55% in the two previous seasons.
The VCRs for HCPs were also below the recommended 75%
threshold in the 17 countries that could provide data
(Figure 1B). The highest VCR reported was in Portugal (67.9%)
in the 2015–16 season and the other VCRs were below 50%
with the exception of England.
Only 11 countries were able to provide data for the VCRs
in those living with a medical risk condition. England,
France, The Netherlands and Scotland were the only coun-
tries to have data for all three seasons (Figure 1C). In the
2015–2016 season, the highest VCR was in Portugal (59.1%)
with Scotland and England reporting VCRs of 48.0% and
45.1%, respectively. The VCRs for the other countries ranged
from 20.0% in the Czech Republic and Hungary to 39.1% in
France.
Implemented policy elements
The policy elements that are implemented in the countries that






























































































































































































































































































































C) Chronic medical conditions
Figure 1. Vaccination coverage rates for; A) elderly, B) healthcare professionals, C)
those with a medical risk condition for seasons 2013–14 (black bars), 2014–15
(grey bars) and 2015–16 (white bars). The dashed horizontal line indicates the
75% target vaccination coverage rate for all groups.
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Recommendations and funding
All countries had recommendations for seasonal influenza
vaccination for the elderly, healthcare professionals and per-
sons with a medical risk condition, although the recommenda-
tions are heterogeneous. For example, the majority of
countries recommend vaccination for those aged 65 years,
while Germany, Greece, Hungary, The Netherlands and Por-
tugal recommend vaccination for those aged and Slovakia for
those aged59 years. In most countries vaccination is recom-
mended for all HCPs, except in Slovakia where it is recom-
mended for HCPs who have close contact with patients or
foci of infection. The chronic medical conditions included in
the recommendations vary between the countries. Season
influenza vaccination is free (vaccine or administration) for
those in the recommended target populations in all countries
except Bulgaria, Estonia and Poland.
National target VCRs and annual monitoring
and communication of VCRs
Nine countries reporting having an objective of 75% VCR in
the target populations, and five reported having a national
action plan to increase VCRs. Six countries reported annual
monitoring and communication of influenza VCRs by target
population, but 13 countries did not reply to this question.
Among the six countries, three reported not having either a tar-
get VCR or a national plan to improve VCR (Hungary, Switzer-
land and the Netherlands), two reported an objective of 75%
VCR and a national plan to increase VCR (Latvia and the UK),
and one, Greece, reported having an objective of 75% VCR
(Table 1).
Annual influenza summit
Eight countries reported have an annual influenza summit
either before or during the influenza season: Greece, Kosovo,
Latvia, Lithuania, Poland, Romania, Serbia and Slovakia.
HCP incentives
Six countries, Czech Republic, England, France, Ireland, The
Netherlands, and Scotland reported having financial incentives
(payment of a fee or additional revenue) for HCPs who admin-
ister the influenza vaccine.
Awareness campaigns
Seventeen countries said they had a seasonal influenza vacci-
nation awareness campaign organized by their national health
authority or vaccination committee (Table 1). The elements of
this campaign varied, but most used flyers in doctors’ waiting
rooms or advertisements in the press for the general public.
The majority also organized advertising or mailings specifi-
cally for healthcare professionals. In the UK, GPs advise the
vaccination on their practice websites and also contact patients
mainly by text messages although some use letters or phone
calls.
Policy elements for program implementation and VCRs
HCP financial incentive was significantly associated with
higher VCRs for the elderly population (correlation coefficient
0.54, p D 0.018) while having a summit before or during
annual influenza vaccination campaign was associated with
lower VCRs in this population (correlation coefficient -0.53,
p D 0.044). Free vaccination showed a borderline significant
association with higher vaccination uptake rates in the elderly
(correlation coefficient 0.43, p D 0.053). The combinations of
HCP financial incentive with free vaccination and HCP finan-
cial incentive with advertisements or mailings to HCPs were
both found to be significantly associated with higher VCRs in
the elderly: correlation coefficient 0.49, p D 0.047 and correla-
tion coefficient 0.79, p D 0.034, respectively, whereas the com-
bination of free vaccination and annual summit was
significantly associated with lower VCRs in the elderly: corre-
lation coefficient -0.70, p D 0.008.
None of the individual policy elements were significantly
associated with higher or lower VCRs for HCPs (Table 2). Two
elements were found to be borderline significant: having an
objective for 75% VCR in targeted groups (correlation coeffi-
cient 0.54, pD 0.088), and having a website for the general pub-
lic (correlation coefficient 0.47, p D 0.054). The combination of
free vaccination and annual monitoring & communication of
VCR by the health authority and the combination of free vacci-
nation and having a website for the general public were found
to be significantly correlated with higher VCRs for HCP: corre-
lation coefficient 0.83, p D 0.042 and correlation coefficient
0.57, p D 0.021, respectively.
The data for VCRs in those with medical risk condition were
insufficient for correlation analyses to be performed.
Discussion
These results confirm that despite national and international
recommendations for seasonal influenza vaccination for the
elderly, HCPs and those with medical risk conditions, the
VCRs that were available for these target groups have not
reached WHO’s target of 75% VCR. We also report that
most of the policy elements did not seem to be associated
with higher VCRs individually, although some combinations
were statistically significantly associated with higher VCRs
for the elderly and HCPs. Unexpectedly, we observed that
having a summit before or during annual influenza vaccina-
tion campaign was associated with lower VCRs in the
elderly. This could be because the countries where this
occurred may not have had sufficiently support for an effec-
tive vaccination campaign. The VCRs for the elderly were
generally lower than those reported for the 2007–2008 sea-
son in our previous survey in most countries.9 However, in
Portugal the VCR increased from 51% in the previous sur-
vey to 68% in the 2015–2016 season and in the UK and
Poland the VCRs were stable.
Best practices should be shared between countries to sup-
port policy changes aimed at improving influenza VCRs and
thus achieving the European Union targets. To enable this, we
need to understand better what facilitators and barriers have
an impact on VCRs. Our previous survey in 16 European
countries in the 2007–08 influenza season showed that moni-
toring and communicating VCRs and sending personal letters
offering free vaccination were correlated with higher VCRs in
the elderly.9 However, in this recent survey these elements
were not associated with higher VCRs in the elderly.
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Monitoring VCRs is a key component in any vaccination pro-
gram to help identify successful policy elements as well as
gaps and weaknesses. This should be done annually and the
results should be available before the next season to take
advantage of the lessons learned and adapt the policy accord-
ingly. Also this monitoring will provide material to communi-
cate broadly on the outcomes of public health intervention,
i.e., pubic money spent to reach an important public health
goal. The VCRs we report are similar to those reported on the
OECD website.10
Although the European countries in this survey all recom-
mend seasonal influenza vaccination for people living with
medical risk conditions, VCRs for this group were available
only in 10 of the 23 countries. Only 17 of the reporting coun-
tries have vaccine coverage data for HCPs. In addition, VCR
monitoring in these risk groups is not systemic in many coun-
tries and the methods used are heterogeneous. One of the prob-
lems is that it is often unclear how the number of individuals
eligible for vaccination in these risk groups is determined. Since
this number is used as the denominator in the VCR calculation,
its accurate estimation is important. As monitoring VCRs is a
key component of any vaccination campaign, monitoring
should be done at least annual and the results should be avail-
able before the next campaign to help build on lessons learned
and adapt the programs accordingly. These data would provide
material for broad communicate on the outcomes of public
health interventions and demonstrate that pubic money had
been well spent to reach an important public health goal.
A Cochrane review of 57 randomized controlled trials
assessing interventions to increase VCR in community-dwell-
ing individuals aged 60 years concluded that, while some
interventions effectively increased VCR the trials were hetero-
geneous, which limited their ability to perform meta-analyses.11
The trials assessed a variety of methods that can be grouped
into increasing community demand, improving access to vacci-
nation and HPC- or healthcare system/targeted interventions;
but no trials assessing government policies were identified.
Another systematic review assessed the effectiveness of inter-
ventions using new information and communication technolo-
gies to promote vaccination uptake and increase vaccination
coverage generally.12 Based on 19 studies, mainly performed in
the United States the conclusion was that although these inter-
ventions seem promising, there is a need for further, more
robust data, including cost-effectiveness data. Our question-
naire did not collect data on the use of these new technologies
but this will be included in future surveys.
A study in Israel sought nurses’ perspectives on facilitators
and barriers for the elderly to accept influenza vaccination.13
The results showed that the healthcare team, particularly physi-
cians, could encourage vaccination through recommendations
Table 2. Implementation of policy elements aimed at increasing influenza vaccination coverage rates and correlation with vaccination coverage rates in healthcare pro-












Recommendation for annual seasonal influenza vaccination Yes 17 27.9 (19.8, 35.9) 21 35.3 (24.4, 46.3)
No 0 — 0 —
Vaccination free for recommended patients (vaccine or
administration)?
Yes 16 29.0 (20.8, 37.2) 19 38.3 (27.0, 49.5)
No 1 NN* 2 7.4 (NN*)
National action plan to improve VCR Yes 4 21.9 (0, 53.9) 5 30.0 (0; 62.8)
No 8 24 (13.9, 34.7) 10 23.8 (9.7, 37.9)
Objective for 75% VCR in targeted groups Yes 7 35.8 (19.0, 52.6) 8 44.6 (25.5, 63.7)
No 4 15.4 (0, 36.2) 5 36.8 (10.7, 62.9)
Yearly national VCR objective Yes 4 27.1 (0, 54.2) 3 39.9 (NN*)
No 8 21.8 (10.1, 33.4) 12 22.4 (10.4; 34.3)
Annual monitoring & communication of VCR, by target by HA Yes 4 32.2 (11.6, 52.7) 5 39.0 (2.7, 75.3)
No 4 14.1 (0; 41.3) 4 30.7 (6.9, 54.5)
Summit before or during annual campaign Yes 6 17.1 (4.7, 29.5) 7 16.3 (2.6, 30.1)
No 6 28.0 (13.0, 42.9) 8 36.8 (16.0, 57.6)
HCP have clear objectives to achieve in high-risk groups (GP
and/or other specialist)
Yes 3 29.4 (0; 83.7) 3 38.3 (0; 109)
No 9 21.6 (12.1, 31.1) 12 22.8 (10.3, 35.2)
HCP financial incentive Yes 5 32.4 (10.3, 54.6) 7 50.6 (29.2, 72.0)
No 11 22.9 (15.2, 30.6) 12 26.5 (14.8; 38.1)
Awareness campaign by HA and/or NVIG Yes 12 27.5 (18.6, 36.3) 15 36.2 (23.9, 48.5)
No 4 26.9 (0; 65.1) 5 24.9 (0; 56.8)
Awareness campaign: TV / radio Yes 12 27.8 (17.3, 38.3) 16 36.2 (21.9, 50.5)
No 5 28.0 (9, 47.1) 5 32.6 (15.3, 49.9)
Awareness campaign: press advertisements for public Yes 12 27.3 (17.5, 37.1) 16 37.5 (24.6, 50.4)
No 5 29.1 (6.5, 51.8) 5 28.3 (0; 59.2)
Awareness campaign: flyers / leaflets/ folders in medical
waiting rooms
Yes 15 25,7 (17.7, 33.6) 18 36.1 (24.3, 47.8)
No 2 44.1 (NN*) 3 30.9 (NN*)
Awareness campaign: website for public Yes 12 31.7 (21.2, 42.2) 17 37.5 (24.7, 50.4)
No 5 18.6 (7, 30.2) 4 26.0 (0, 57.7)
Awareness campaign: advertisements or mailings to HCP Yes 11 28.1 (18.1, 38.0) 14 40.8 (26.5, 55.1)
No 6 27.6 (8.0, 47.1) 7 24.3 (6.0, 42.6)
NN: not calculated due to small sample size.
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and showing that they themselves were vaccinated. Other facili-
tators identified were easy access and free vaccine, influence
from the media, family and social circles. The barriers identified
included difficult access, not believing that the vaccine works,
and fear of adverse effects or getting influenza from the vaccine.
In addition, personal beliefs and influence from the media and
social circles could also be barriers.
A study in Spain reported that influenza VCR in patients
aged  65 years was higher in those whose primary care physi-
cian had been vaccinated than in those whose physician had
not (57.3% vs. 55.2%, p D 0.008) and this remained significant
after adjustment for age, region, and opinions on vaccine effec-
tiveness.14 Although this observation needs to be confirmed, it
may be useful to target HCPs with interventions to improve
their opinions and attitudes about influenza vaccination as a
means of increasing VCR among their at-risk patients.
In the USA, it has been reported that employer vaccination
requirements for HCPs and offering free, on-site vaccination
were associated with high VCRs.15 In Switzerland, a study to
identify why nurses refused influenza vaccination reported
three interrelated factors; their perception of being in an
untrustworthy environment, which restricts their decisional
autonomy and seems to work against their aim to maintain a
strong and healthy body.16 In England, the national NHS lead-
ers wrote to all staff to remind them of their ‘professional duty
to protect their patients’ for the 2017–2018 season. They have
urged all local NHS trusts to make influenza vaccination avail-
able to their staff for the season and they have said that all staff
that refuse influenza vaccination will have to give their reasons,
which will be recorded.17
We recognize that our analyses have some limitations which
limit our ability to compare results between countries and to
interpret the data. First, the policy elements were not examined
in detail but there could be important differences between
countries even for elements that are classified as the same. For
example, we did not collect information about the timing and
duration of awareness campaigns which would have an obvious
impact on their efficacy. Second, we did not collect information
about how long the individual elements had been in place and
it is possible that if some elements were only recently intro-
duced they would perhaps not have been reached their optimal
efficacy. Lastly, despite all the countries surveyed being in
Europe there will be differences in culture, religious beliefs and
socioeconomic factors that can also have an impact on VCRs
but our survey approach was unable to collect this level of
information.
Vaccination in general, including influenza vaccination, is a
much debated subject, which may have an impact on individu-
als’ confidence in vaccination and therefore influence their
decision to be vaccinated or not. It has been suggested that evi-
dence-based socio-psychological items could be included in
national immunization surveys to evaluate the public’s percep-
tion and identify emerging concerns which could then be
addressed proactively in the awareness-raising campaigns.18
Although vaccination policies are decided at the national or
regional level, the European Union is keen to support coopera-
tion and exchange of information on national immunization
programs between Member States and concrete joint actions
are being planned.19,20 National immunization programs are
organized differently between countries therefore awareness-
raising campaigns are better organized at the national/regional
level so that they can be tailored to the circumstances of each
country/region. This collaborative approach should positively
impact influenza vaccination policies and ultimately VCRs in
the target groups.
Conclusion
European VCRs vary widely between the elderly, HCPs and
those with medical risk conditions despite all countries iden-
tifying them as target groups in their recommendations for
seasonal influenza vaccination. Over the three influenza sea-
sons analyzed here, the VCRs did not reach the 75% target
set by the WHO and many national health authorities; they
were mainly stable, at best, but some decreases were
observed. Since the initial survey during the 2007–2008
influenza season, VCRs have decreased in the elderly in the
majority of countries, thus, achieving high VCRs in the
elderly and the other target groups is still a major public
health challenge in Europe which could be addressed by the
identification, assessment and sharing of best practice for
influenza vaccination policies.
Materials and methods
Data sources. At the time of the survey in February 2016
there were 22 members from 20 European countries in
RAISE. RAISE is an informal group of national experts in
the field of vaccination and influenza prevention who agreed
to participate in RAISE (see list of current members in
Appendix). They are mainly academic researchers or
employed by public institutions. RAISE’s goal is to achieve
maximum influenza vaccination uptake in the at-risk groups,
as defined by the WHO.21 The achieve this, the members
meet regularly to exchange about what influenza prevention
and influenza vaccination awareness activities are carried out
in their country with the aim of developing synergy between
the members and their activities. They discuss public health
and individual health issues related to influenza control and
prevention and propose and implement awareness activities
to improve influenza vaccination coverage, targeting health-
care professionals and the general public. The meeting and
logistical costs are paid by an unrestricted grant from Sanofi
Pasteur; the members are not paid for their RAISE-related
activities.
The methods used were similar to those used for the initial
survey published in 2012.9 The survey questionnaire, written in
English, contained closed questions (yes/no) but allowed the
respondents to provide additional information as previously
described. The questions were based on a previous literature
review to identify policy elements that potentially influence
VCRs. In this current study, we collected data about the elderly,
as done previously, and also expanded to collect similar data for
HCPs and those living with medical risk conditions. Although
there was no formal validation of the survey, the data collected
were compared those available from other sources, in particular
in the latest ECDC report covering the 2007/08 to 2014/15
European influenza seasons.22
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The questionnaire was sent out in February 2016 and returned
between March 2016 and July 2016 to the 22 RAISE group mem-
bers; 21 members responded (see Appendix for names of those
who responded). This data collection was coordinated by one of
the authors (PRB).In addition, in May 2017 we asked the RAISE
members to verify the data and update them, if necessary.
Data analyses. The analyses were primarily descriptive, as
previously described.9 Briefly, for the description of the pres-
ence or absence of policy elements covered by the question-
naire, a score of 1 or 0 was attributed for a given policy element,
e.g., monitoring annual VCRs, if the country replied ‘yes’ or
‘no’, respectively. When the effect of two or three program ele-
ments was assessed, a score of 1 was attributed for a given pol-
icy element when countries responded ‘yes’ for all elements,
and 0 if the responded ‘no’ for at least one element. Countries
were excluded from the analysis for the element if there was no
response (missing data), thereby avoiding inappropriately
deflated averages by interpreting non-responses as negative
responses. We assessed the association between implemented
policy elements and vaccine coverage rates by Spearman’s cor-
relation coefficient (Spearman’s rho). Correlation coefficients
range from –1 for a perfect negative relationship to C1 for a
perfect positive relationship, with 0 indicating no correlation.
For all statistical tests, the threshold for statistical significance
for the two-sided p values was set at<0.05. We performed mul-
tiple regression analyses but they provided no additional infor-
mation and, given the limited data available, the results are not
robust and interpretation is difficult (results not shown).
The data were analyzed using Microsoft Excel 2013. The sta-
tistical analyses were done using IBM SPSS version 22.
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